Australian CSL has released topline results from the Phase III AEGIS-II trial of CSL112 in patients following an acute myocardial infarction (MI). Results showed that the drug failed to meet its primary endpoint of a reduction in the risk of major adverse cardiovascular events (MACE) at 90 days.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,